标题
Targeting the ATR-CHK1 Axis in Cancer Therapy
作者
关键词
-
出版物
Cancers
Volume 9, Issue 12, Pages 41
出版商
MDPI AG
发表日期
2017-04-28
DOI
10.3390/cancers9050041
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Coupling of Homologous Recombination and the Checkpoint by ATR
- (2017) Rémi Buisson et al. MOLECULAR CELL
- Abstract CT012: Phase 1 trial of first-in-class ATR inhibitor VX-970 in combination with cisplatin (Cis) in patients (pts) with advanced solid tumors (NCT02157792):
- (2016) Geoffrey Shapiro et al. CANCER RESEARCH
- Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer
- (2016) Giorgio Scagliotti et al. INVESTIGATIONAL NEW DRUGS
- Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer
- (2016) David Hong et al. JOURNAL OF CLINICAL ONCOLOGY
- CHK1 Inhibition Radiosensitizes Head and Neck Cancers to Paclitaxel-Based Chemoradiotherapy
- (2016) H. E. Barker et al. MOLECULAR CANCER THERAPEUTICS
- Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei
- (2016) Magnus T. Dillon et al. MOLECULAR CANCER THERAPEUTICS
- Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid Tumors
- (2016) Emiliano Calvo et al. ONCOLOGY
- Targeting the kinase activities of ATR and ATM exhibits antitumoral activity in mouse models ofMLL-rearranged AML
- (2016) Isabel Morgado-Palacin et al. Science Signaling
- ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A
- (2016) Chris T. Williamson et al. Nature Communications
- Targeting radioresistant breast cancer cells by single agent CHK1 inhibitor via enhancing replication stress
- (2016) Yao Zhang et al. Oncotarget
- A synthetic lethal screen identifies ATR-inhibition as a novel therapeutic approach for POLD1-deficient cancers
- (2016) Sandra Hocke et al. Oncotarget
- Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities
- (2016) Kumar Sanjiv et al. Cell Reports
- Targeting the kinase activities of ATR and ATM exhibits antitumoral activity in mouse models ofMLL-rearranged AML
- (2016) Isabel Morgado-Palacin et al. Science Signaling
- Phase I study of LY2603618, a CHK1 inhibitor, in combination with gemcitabine in Japanese patients with solid tumors
- (2015) Toshihiko Doi et al. ANTI-CANCER DRUGS
- ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells
- (2015) M. Kwok et al. BLOOD
- Topotecan synergizes with CHEK1 (CHK1) inhibitor to induce apoptosis in ovarian cancer cells
- (2015) Marianne K Kim et al. BMC CANCER
- DNA damage control: regulation and functions of checkpoint kinase 1
- (2015) Veronique A. J. Smits et al. FEBS Journal
- Drugging ATR: progress in the development of specific inhibitors for the treatment of cancer
- (2015) Kevin M Foote et al. Future Medicinal Chemistry
- Pharmacologic inhibition of ATR and ATM offers clinically important distinctions to enhancing platinum or radiation response in ovarian, endometrial, and cervical cancer cells
- (2015) Pang-ning Teng et al. GYNECOLOGIC ONCOLOGY
- Phase I Dose-Escalation Trial of Checkpoint Kinase 1 Inhibitor MK-8776 As Monotherapy and in Combination With Gemcitabine in Patients With Advanced Solid Tumors
- (2015) Adil I. Daud et al. JOURNAL OF CLINICAL ONCOLOGY
- Abstract C60: Pre-clinical efficacy of the ATR inhibitor AZD6738 in combination with the PARP inhibitor olaparib
- (2015) Alan Lau et al. MOLECULAR CANCER THERAPEUTICS
- mTORC1 and DNA-PKcs as novel molecular determinants of sensitivity to Chk1 inhibition
- (2015) Andrew J. Massey et al. Molecular Oncology
- Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition
- (2015) Fiona K. Middleton et al. Oncotarget
- The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma
- (2015) Mike I. Walton et al. Oncotarget
- Identification of novel, in vivo active Chk1 inhibitors utilizing structure guided drug design
- (2015) Andrew J. Massey et al. Oncotarget
- The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo
- (2015) Frank P. Vendetti et al. Oncotarget
- A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments
- (2015) Kareem N. Mohni et al. PLoS One
- Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970
- (2015) Amy B. Hall et al. Oncotarget
- Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers
- (2014) Christopher Bryant et al. BMC CANCER
- Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors
- (2014) Edward Sausville et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- ATR Inhibitors VE-821 and VX-970 Sensitize Cancer Cells to Topoisomerase I Inhibitors by Disabling DNA Replication Initiation and Fork Elongation Responses
- (2014) R. Josse et al. CANCER RESEARCH
- ATR Pathway Inhibition Is Synthetically Lethal in Cancer Cells with ERCC1 Deficiency
- (2014) K. N. Mohni et al. CANCER RESEARCH
- Understanding nucleotide excision repair and its roles in cancer and ageing
- (2014) Jurgen A. Marteijn et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- ATR inhibition preferentially targets homologous recombination-deficient tumor cells
- (2014) M Krajewska et al. ONCOGENE
- PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells
- (2013) Laurence Booth et al. CANCER BIOLOGY & THERAPY
- ATR Inhibition Broadly Sensitizes Ovarian Cancer Cells to Chemotherapy Independent of BRCA Status
- (2013) C. J. Huntoon et al. CANCER RESEARCH
- Sensitization of Pancreatic Cancer to Chemoradiation by the Chk1 Inhibitor MK8776
- (2013) C. G. Engelke et al. CLINICAL CANCER RESEARCH
- Structure-based design, discovery and development of checkpoint kinase inhibitors as potential anticancer therapies
- (2013) Thomas P Matthews et al. Expert Opinion on Drug Discovery
- Checkpoint Kinase Inhibitor AZD7762 Overcomes Cisplatin Resistance in Clear Cell Carcinoma of the Ovary
- (2013) Hiroaki Itamochi et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor
- (2013) Constance King et al. INVESTIGATIONAL NEW DRUGS
- Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): A Potent and Selective Inhibitor of ATR Protein Kinase with Monotherapy in Vivo Antitumor Activity
- (2013) Kevin M. Foote et al. JOURNAL OF MEDICINAL CHEMISTRY
- Chk1/2 Inhibition Overcomes the Cisplatin Resistance of Head and Neck Cancer Cells Secondary to the Loss of Functional p53
- (2013) M. A. Gadhikar et al. MOLECULAR CANCER THERAPEUTICS
- Causes and consequences of replication stress
- (2013) Michelle K. Zeman et al. NATURE CELL BIOLOGY
- Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Protein Kinase Inhibition Is Synthetically Lethal in XRCC1 Deficient Ovarian Cancer Cells
- (2013) Rebeka Sultana et al. PLoS One
- Comparative Analysis of Radiosensitizers for K-RAS Mutant Rectal Cancers
- (2013) Laura B. Kleiman et al. PLoS One
- DNA Damage Sensing by the ATM and ATR Kinases
- (2013) A. Marechal et al. Cold Spring Harbor Perspectives in Biology
- Targeting radiation-resistant hypoxic tumour cells through ATR inhibition
- (2012) I M Pires et al. BRITISH JOURNAL OF CANCER
- Evaluation of checkpoint kinase targeting therapy in Acute Myeloid Leukemia with complex karyotype
- (2012) Christine Didier et al. CANCER BIOLOGY & THERAPY
- Base excision repair and cancer
- (2012) Susan S. Wallace et al. CANCER LETTERS
- ATR-ATRIP Kinase Complex Triggers Activation of the Fanconi Anemia DNA Repair Pathway
- (2012) T. Shigechi et al. CANCER RESEARCH
- Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1
- (2012) Sean Vance et al. CELL CYCLE
- Combined inhibition of Chk1 and Wee1: In vitro synergistic effect translates to tumor growth inhibition in vivo
- (2012) Laura Carrassa et al. CELL CYCLE
- Effects of Selective Checkpoint Kinase 1 Inhibition on Cytarabine Cytotoxicity in Acute Myelogenous Leukemia Cells In Vitro
- (2012) E. L. Schenk et al. CLINICAL CANCER RESEARCH
- CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs
- (2012) M. I. Walton et al. CLINICAL CANCER RESEARCH
- Phase I and Pharmacologic Trial of Cytosine Arabinoside with the Selective Checkpoint 1 Inhibitor Sch 900776 in Refractory Acute Leukemias
- (2012) J. E. Karp et al. CLINICAL CANCER RESEARCH
- Discovery of Checkpoint Kinase Inhibitor (S)-5-(3-Fluorophenyl)-N-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide (AZD7762) by Structure-Based Design and Optimization of Thiophenecarboxamide Ureas
- (2012) Vibha Oza et al. JOURNAL OF MEDICINAL CHEMISTRY
- Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation
- (2012) E Fokas et al. Cell Death & Disease
- Inhibition of checkpoint kinase 1 sensitizes lung cancer brain metastases to radiotherapy
- (2011) Heekyoung Yang et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- ATR signalling: more than meeting at the fork
- (2011) Edward A. Nam et al. BIOCHEMICAL JOURNAL
- Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines
- (2011) A Peasland et al. BRITISH JOURNAL OF CANCER
- Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation
- (2011) Kurtis D. Davies et al. CANCER BIOLOGY & THERAPY
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Replication stress activates DNA polymerase alpha-associated Chk1
- (2011) Lorena Taricani et al. CELL CYCLE
- Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy
- (2011) M Bartucci et al. CELL DEATH AND DIFFERENTIATION
- Targeting the S and G2 checkpoint to treat cancer
- (2011) Tao Chen et al. DRUG DISCOVERY TODAY
- Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR
- (2011) David W. Schoppy et al. JOURNAL OF CLINICAL INVESTIGATION
- Discovery of Potent and Selective Inhibitors of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Protein Kinase as Potential Anticancer Agents
- (2011) Jean-Damien Charrier et al. JOURNAL OF MEDICINAL CHEMISTRY
- Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
- (2011) T. J. Guzi et al. MOLECULAR CANCER THERAPEUTICS
- Preclinical Development of the Novel Chk1 Inhibitor SCH900776 in Combination with DNA-Damaging Agents and Antimetabolites
- (2011) R. Montano et al. MOLECULAR CANCER THERAPEUTICS
- Targeting ATR and Chk1 kinases for cancer treatment: A new model for new (and old) drugs
- (2011) Luis I. Toledo et al. Molecular Oncology
- Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR
- (2011) Philip M Reaper et al. Nature Chemical Biology
- Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors
- (2011) Matilde Murga et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations
- (2011) Luis I Toledo et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication
- (2011) C. S. Sorensen et al. NUCLEIC ACIDS RESEARCH
- Knockdown of Chk1 sensitizes human colon carcinoma HCT116 cells in a p53-dependent manner to lidamycin through abrogation of a G2/M checkpoint and induction of apoptosis
- (2010) Yu Pan et al. CANCER BIOLOGY & THERAPY
- Combining ATR Suppression with Oncogenic Ras Synergistically Increases Genomic Instability, Causing Synthetic Lethality or Tumorigenesis in a Dosage-Dependent Manner
- (2010) O. Gilad et al. CANCER RESEARCH
- Mechanism of Radiosensitization by the Chk1/2 Inhibitor AZD7762 Involves Abrogation of the G2Checkpoint and Inhibition of Homologous Recombinational DNA Repair
- (2010) Meredith A. Morgan et al. CANCER RESEARCH
- In vitro and In vivo Radiation Sensitization of Human Tumor Cells by a Novel Checkpoint Kinase Inhibitor, AZD7762
- (2010) J. B. Mitchell et al. CLINICAL CANCER RESEARCH
- New Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling Network
- (2010) Y. Dai et al. CLINICAL CANCER RESEARCH
- Checkpoint kinase inhibitor synergizes with DNA-damaging agents in G1checkpoint-defective neuroblastoma
- (2010) Hong Xu et al. INTERNATIONAL JOURNAL OF CANCER
- Poly(ADP-Ribose) Polymerase 1 Modulates the Lethality of CHK1 Inhibitors in Carcinoma Cells
- (2010) C. Mitchell et al. MOLECULAR PHARMACOLOGY
- Status of p53 in human cancer cells does not predict efficacy of CHK1 kinase inhibitors combined with chemotherapeutic agents
- (2010) S Zenvirt et al. ONCOGENE
- Reconstitution of RPA-covered single-stranded DNA-activated ATR-Chk1 signaling
- (2010) J.-H. Choi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PF-00477736 Mediates Checkpoint Kinase 1 Signaling Pathway and Potentiates Docetaxel-Induced Efficacy in Xenografts
- (2009) C. Zhang et al. CLINICAL CANCER RESEARCH
- ATR signaling at a glance
- (2009) B. Shiotani et al. JOURNAL OF CELL SCIENCE
- Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer
- (2009) David O Azorsa et al. Journal of Translational Medicine
- CHK1 inhibition as a strategy for targeting fanconi anemia (FA) DNA repair pathway deficient tumors
- (2009) Clark C Chen et al. Molecular Cancer
- Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells
- (2009) L. A. Parsels et al. MOLECULAR CANCER THERAPEUTICS
- Cisplatin-Induced DNA Damage Activates Replication Checkpoint Signaling Components that Differentially Affect Tumor Cell Survival
- (2009) J. M. Wagner et al. MOLECULAR PHARMACOLOGY
- Inhibition of ATR protein kinase activity by schisandrin B in DNA damage response
- (2009) H. Nishida et al. NUCLEIC ACIDS RESEARCH
- Checkpoint Kinase 1 Down-Regulation by an Inducible Small Interfering RNA Expression System Sensitized In vivo Tumors to Treatment with 5-Fluorouracil
- (2008) M. Ganzinelli et al. CLINICAL CANCER RESEARCH
- Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1
- (2008) A. Blasina et al. MOLECULAR CANCER THERAPEUTICS
- AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies
- (2008) S. D. Zabludoff et al. MOLECULAR CANCER THERAPEUTICS
- ATR: an essential regulator of genome integrity
- (2008) Karlene A. Cimprich et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Oncogenes and Cancer
- (2008) Carlo M. Croce NEW ENGLAND JOURNAL OF MEDICINE
- An Oncogene-Induced DNA Damage Model for Cancer Development
- (2008) T. D. Halazonetis et al. SCIENCE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started